Track topics on Twitter Track topics that are important to you
1435 Kensington Square Court
United States of America
Chugai looks to invest some $221M into a Singapore research center for biopharma by 2021, seeking to better compete with a host of nimble bioventures.
Mavupharma raised $20mm in a Series A financing led by Frazier Healthcare Partners, which adds a board member and was joined by Alpine BioVentures.
AnchorDx Corp of Guangzhou raised $28 million in a Series B round to develop precision oncology products using next-generation sequencing technology. The company's major focus applies NGS to methylate...
Neuspera Medical, a California neuromodulation company, completed the initial closing of a $26 million Series B round, led by 6 Dimensions Capital. 6 Dimensions was formed in 2017 by the merger of two...
Viela Bio, a brand new spinout from MedImmune, announced a $250 million Series A funding led by three China investors: Shanghai's 6 Dimensions Capital (an investment firm formed in 2017 by the merger ...
Engine Biosciences, a San Francisco-Singapore startup, raised $10 million in seed capital to develop its artificial intelligence/genomics drug development platform. The company claims its platform, wh...
In an undisclosed late-stage equity round, Aegea Medical Inc. (endometrial ablation device) raised $30mm from Perceptive Advisors and an additional $10mm from returning backers, including Alloy Ventur...
Frontline BioVentures is a China-based premier venture capital firm specializing in investments in innovative life science companies. It focuses on business within strategic life ...
BioVentures, Inc. is committed to the highest levels of scholarship through the submission of original research to peer reviewed publications and presentation of our data at scientific conferences. In...
Alpine BioVentures is a venture capital firm committed to investing in and building revolutionary healthcare companies. It brings a unique perspective to identify game-changing sc...
Headquartered near Research Triangle Park, NC, APR is majority owned and virtually run by Cato BioVentures. APR will work with Advanced Targeting Systems, Cato Research and Cato BioVentures to develop...
HTI was formed in 2004 as a majority-owned portfolio company of Cato BioVentures. Through its strategic development relationship with Cato BioVentures and its contract research and development affilia...
We have published hundreds of BioVentures, Inc. news stories on BioPortfolio along with dozens of BioVentures, Inc. Clinical Trials and PubMed Articles about BioVentures, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioVentures, Inc. Companies in our database. You can also find out about relevant BioVentures, Inc. Drugs and Medications on this site too.